Christopher Mutz, who leads the Rare Disease unit at ANI Pharmaceuticals, executed an insider sale of 3,162 shares of common stock on March 13, 2026, according to a newly filed Form 4 with the Securities and Exchange Commission.
The transaction was recorded at a weighted average price of $71.64 per share, producing total proceeds of $226,525. Trade prices in the block ranged from $70.27 at the low end to $72.62 at the high end. After the sale, Mutz directly holds 91,309 shares of ANI Pharmaceuticals.
Company filings indicate the disposition was made under a pre-arranged Rule 10b5-1 trading plan that Mutz adopted on June 16, 2025. The notice did not disclose any additional changes to his holdings beyond the post-sale figure.
ANI Pharmaceuticals shares have declined approximately 11% year-to-date and were trading at $70.36 at the time of the most recent reporting. The insider sale comes in the wake of the company’s strong reported results for the fourth quarter of 2025.
ANI reported earnings per share of $2.33 for Q4 2025, beating the market forecast of $1.97 - a positive surprise of 18.27%. Quarterly revenue was reported at $247.1 million, above the anticipated $232.37 million. Despite the top- and bottom-line beats, the company’s stock fell in premarket trading following the results.
Key points
- Insider sale: Christopher Mutz sold 3,162 shares on March 13, 2026, for $226,525 at a weighted average price of $71.64.
- Earnings beat: ANI reported Q4 2025 EPS of $2.33 versus the $1.97 forecast and revenue of $247.1 million versus $232.37 million expected.
- Market reaction and positioning: Shares were down roughly 11% year-to-date and slipped in premarket trading despite the earnings and revenue beat.
Risks and uncertainties
- Stock volatility - The company’s shares have moved lower year-to-date and fell in premarket trading after reporting results, indicating ongoing market uncertainty.
- Insider activity interpretation - The sale was completed under a pre-set Rule 10b5-1 plan; observers may view insider transactions differently, but the filing does not provide further context.
- Limited disclosure - Public filings present the transaction and aggregate holdings, but do not provide additional commentary or rationale from management regarding the sale or short-term outlook.
This report presents the factual details disclosed in the SEC filing and the company’s published quarterly results. No additional commentary or interpretation beyond those disclosures has been included.